Current Advances in Sustained Release Microneedles

Guangsheng Du; Xun Sun

doi:10.1055/s-0040-1701435

Pharmaceutical Fronts, Inhaltsverzeichnis

CC BY 4.0 · Pharmaceutical Fronts 2020; 02(01): e11-e22
DOI: 10.1055/s-0040-1701435

Review Article

Georg Thieme Verlag KG Stuttgart · New York

Current Advances in Sustained Release Microneedles

Autor*innen

Guangsheng Du

¹Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, PR China
Xun Sun

¹Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, PR China

Abstract

Microneedles have been extensively investigated for intradermal delivery of drugs and vaccines due to advantages including high skin delivery efficiency, improved patient compliance, and potential for self-administration. However, traditional microneedles cannot regulate the release kinetics of payloads, limiting therapeutic utility of the biotherapeutics. Recently, several types of microneedles with sustained release properties, including slow-dissolving microneedles made of hydrophilic polymers, degradable microneedles made of hydrophobic polymers, and bioresponsive microneedles made of bioresponsive polymers, have been developed and investigated for intradermal delivery of the biotherapeutics, aiming for improving their therapeutic potency, reducing side effects and administration frequency, and further improving patient compliance. In this review, we introduced different types of microneedles that have been designed for sustained release of the payloads, summarized various applications of these microneedles, and discussed the future prospects of this technology.

Keywords

sustained release - polymeric microneedles - drug delivery - vaccines

Volltext

Referenzen

References
1 van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release 2012; 161 (02) 645-655
2 Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012; 64 (14) 1547-1568
3 McAllister DV, Wang PM, Davis SP. , et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci U S A 2003; 100 (24) 13755-13760
4 Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008; 26 (11) 1261-1268
5 Rouphael NG, Paine M, Mosley R. , et al; TIV-MNP 2015 Study Group. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet 2017; 390 (10095); 649-658
6 Chu LY, Ye L, Dong K, Compans RW, Yang C, Prausnitz MR. Enhanced stability of inactivated influenza vaccine encapsulated in dissolving microneedle patches. Pharm Res 2016; 33 (04) 868-878
7 Mistilis MJ, Bommarius AS, Prausnitz MR. Development of a thermostable microneedle patch for influenza vaccination. J Pharm Sci 2015; 104 (02) 740-749
8 Schoellhammer CM, Blankschtein D, Langer R. Skin permeabilization for transdermal drug delivery: recent advances and future prospects. Expert Opin Drug Deliv 2014; 11 (03) 393-407
9 Cevc G, Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J Control Release 2010; 141 (03) 277-299
10 Ito Y, Hagiwara E, Saeki A, Sugioka N, Takada K. Feasibility of microneedles for percutaneous absorption of insulin. Eur J Pharm Sci 2006; 29 (01) 82-88
11 Lee JW, Choi SO, Felner EI, Prausnitz MR. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small 2011; 7 (04) 531-539
12 Indermun S, Luttge R, Choonara YE. , et al. Current advances in the fabrication of microneedles for transdermal delivery. J Control Release 2014; 185: 130-138
13 Larrañeta E, McCrudden MT, Courtenay AJ, Donnelly RF. Microneedles: a new frontier in nanomedicine delivery. Pharm Res 2016; 33 (05) 1055-1073
14 Tuan-Mahmood TM, McCrudden MT, Torrisi BM. , et al. Microneedles for intradermal and transdermal drug delivery. Eur J Pharm Sci 2013; 50 (05) 623-637
15 Sullivan SP, Murthy N, Prausnitz MR. Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater 2008; 20 (05) 933-938
16 Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release 2005; 104 (01) 51-66
17 Lee K, Lee CY, Jung H. Dissolving microneedles for transdermal drug administration prepared by stepwise controlled drawing of maltose. Biomaterials 2011; 32 (11) 3134-3140
18 Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials 2008; 29 (13) 2113-2124
19 Lee JW, Han MR, Park JH. Polymer microneedles for transdermal drug delivery. J Drug Target 2013; 21 (03) 211-223
20 Leone M, Mönkäre J, Bouwstra JA, Kersten G. Dissolving microneedle patches for dermal vaccination. Pharm Res 2017; 34 (11) 2223-2240
21 Herwadkar A, Banga AK. Peptide and protein transdermal drug delivery. Drug Discov Today Technol 2012; 9 (02) e71-e174
22 Wu F, Yang S, Yuan W, Jin T. Challenges and strategies in developing microneedle patches for transdermal delivery of protein and peptide therapeutics. Curr Pharm Biotechnol 2012; 13 (07) 1292-1298
23 Matsuo K, Yokota Y, Zhai Y. , et al. A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. J Control Release 2012; 161 (01) 10-17
24 Hiraishi Y, Nakagawa T, Quan YS. , et al. Performance and characteristics evaluation of a sodium hyaluronate-based microneedle patch for a transcutaneous drug delivery system. Int J Pharm 2013; 441 (1–2): 570-579
25 Guo L, Chen J, Qiu Y, Zhang S, Xu B, Gao Y. Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant. Int J Pharm 2013; 447 (1–2): 22-30
26 Sullivan SP, Koutsonanos DG, Del Pilar Martin M. , et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010; 16 (08) 915-920
27 Edens C, Dybdahl-Sissoko NC, Weldon WC, Oberste MS, Prausnitz MR. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. Vaccine 2015; 33 (37) 4683-4690
28 Edens C, Collins ML, Goodson JL, Rota PA, Prausnitz MR. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine 2015; 33 (37) 4712-4718
29 Vassilieva EV, Kalluri H, McAllister D. , et al. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. Drug Deliv Transl Res 2015; 5 (04) 360-371
30 Quinn HL, Kearney MC, Courtenay AJ, McCrudden MT, Donnelly RF. The role of microneedles for drug and vaccine delivery. Expert Opin Drug Deliv 2014; 11 (11) 1769-1780
31 Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. In: Compans RW, Orenstein WA. , eds. Vaccines for Pandemic Influenza. Berlin: Springer; 2009: 369-393
32 Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv 2010; 17 (04) 187-207
33 Li G, Badkar A, Nema S, Kolli CS, Banga AK. In vitro transdermal delivery of therapeutic antibodies using maltose microneedles. Int J Pharm 2009; 368 (1–2): 109-115
34 Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23 (09) 1073-1078
35 Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev 2016; 116 (04) 2602-2663
36 Hong X, Wei L, Wu F. , et al. Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine. Drug Des Devel Ther 2013; 7: 945-952
37 Ye Y, Yu J, Wen D, Kahkoska AR, Gu Z. Polymeric microneedles for transdermal protein delivery. Adv Drug Deliv Rev 2018; 127: 106-118
38 Chen MC, Huang SF, Lai KY, Ling MH. Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination. Biomaterials 2013; 34 (12) 3077-3086
39 Xie Y, Xu B, Gao Y. Controlled transdermal delivery of model drug compounds by MEMS microneedle array. Nanomedicine 2005; 1 (02) 184-190
40 Chu LY, Prausnitz MR. Separable arrowhead microneedles. J Control Release 2011; 149 (03) 242-249
41 Lee K, Jung H. Drawing lithography for microneedles: a review of fundamentals and biomedical applications. Biomaterials 2012; 33 (30) 7309-7326
42 Moga KA, Bickford LR, Geil RD. , et al. Rapidly-dissolvable microneedle patches via a highly scalable and reproducible soft lithography approach. Adv Mater 2013; 25 (36) 5060-5066
43 Kim JD, Kim M, Yang H, Lee K, Jung H. Droplet-born air blowing: novel dissolving microneedle fabrication. J Control Release 2013; 170 (03) 430-436
44 Wang W, Nema S, Teagarden D. Protein aggregation--pathways and influencing factors. Int J Pharm 2010; 390 (02) 89-99
45 Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol 2014; 11 (02) 99-109
46 Zhu G, Mallery SR, Schwendeman SP. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). Nat Biotechnol 2000; 18 (01) 52-57
47 Rothe A, Power BE, Hudson PJ. Therapeutic advances in rheumatology with the use of recombinant proteins. Nat Clin Pract Rheumatol 2008; 4 (11) 605-614
48 Vora LK, Donnelly RF, Larrañeta E, González-Vázquez P, Thakur RRS, Vavia PR. Novel bilayer dissolving microneedle arrays with concentrated PLGA nano-microparticles for targeted intradermal delivery: proof of concept. J Control Release 2017; 265: 93-101
49 Ke CJ, Lin YJ, Hu YC. , et al. Multidrug release based on microneedle arrays filled with pH-responsive PLGA hollow microspheres. Biomaterials 2012; 33 (20) 5156-5165
50 Park JH, Allen MG, Prausnitz MR. Polymer microneedles for controlled-release drug delivery. Pharm Res 2006; 23 (05) 1008-1019
51 Palakurthi NK, Correa ZM, Augsburger JJ, Banerjee RK. Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study. J Ocul Pharmacol Ther 2011; 27 (02) 151-156
52 Kim M, Jung B, Park JH. Hydrogel swelling as a trigger to release biodegradable polymer microneedles in skin. Biomaterials 2012; 33 (02) 668-678
53 Demuth PC, Garcia-Beltran WF, Ai-Ling ML, Hammond PT, Irvine DJ. Composite dissolving microneedles for coordinated control of antigen and adjuvant delivery kinetics in transcutaneous vaccination. Adv Funct Mater 2013; 23 (02) 161-172
54 Li W, Terry RN, Tang J, Feng MR, Schwendeman SP, Prausnitz MR. Rapidly separable microneedle patch for the sustained release of a contraceptive. Nat Biomed Eng 2019; 3 (03) 220-229
55 Donnelly RF, Morrow DI, Singh TR. , et al. Processing difficulties and instability of carbohydrate microneedle arrays. Drug Dev Ind Pharm 2009; 35 (10) 1242-1254
56 DeMuth PC, Min Y, Irvine DJ, Hammond PT. Implantable silk composite microneedles for programmable vaccine release kinetics and enhanced immunogenicity in transcutaneous immunization. Adv Healthc Mater 2014; 3 (01) 47-58
57 Wang C, Ye Y, Hochu GM, Sadeghifar H, Gu Z. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Lett 2016; 16 (04) 2334-2340
58 Chen BZ, Ashfaq M, Zhu DD, Zhang XP, Guo XD. Controlled delivery of insulin using rapidly separating microneedles fabricated from genipin-crosslinked gelatin. Macromol Rapid Commun 2018; 39 (20) e1800075
59 Lee J, Park SH, Seo IH, Lee KJ, Ryu W. Rapid and repeatable fabrication of high A/R silk fibroin microneedles using thermally-drawn micromolds. Eur J Pharm Biopharm 2015; 94: 11-19
60 Tsioris K, Raja WK, Pritchard EM. , et al. Fabrication of silk microneedles for controlled-release drug delivery. Adv Funct Mater 2012; 22 (02) 330-335
61 Ye Y, Wang C, Zhang X. , et al. A melanin-mediated cancer immunotherapy patch. Sci Immunol 2017; 2 (17) eaan5692
62 DeMuth PC, Moon JJ, Suh H, Hammond PT, Irvine DJ. Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery. ACS Nano 2012; 6 (09) 8041-8051
63 Di J, Yao S, Ye Y. , et al. Stretch-triggered drug delivery from wearable elastomer films containing therapeutic depots. ACS Nano 2015; 9 (09) 9407-9415
64 Ye Y, Yu J, Wang C. , et al. Microneedles integrated with pancreatic cells and synthetic glucose-signal amplifiers for smart insulin delivery. Adv Mater 2016; 28 (16) 3115-3121
65 Ye Y, Wang J, Hu Q. , et al. Synergistic transcutaneous immunotherapy enhances antitumor immune responses through delivery of checkpoint inhibitors. ACS Nano 2016; 10 (09) 8956-8963
66 Wang J, Ye Y, Yu J. , et al. Core-shell microneedle gel for self-regulated insulin delivery. ACS Nano 2018; 12 (03) 2466-2473
67 Chen W, Tian R, Xu C. , et al. Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy. Nat Commun 2017; 8 (01) 1777
68 Koh LD, Cheng Y, Teng CP. , et al. Structures, mechanical properties and applications of silk fibroin materials. Prog Polym Sci 2015; 46: 86-110
69 Liu Q, Liu H, Fan Y. Preparation of silk fibroin carriers for controlled release. Microsc Res Tech 2017; 80 (03) 312-320
70 You X, Chang JH, Ju BK. , et al. Rapidly dissolving fibroin microneedles for transdermal drug delivery. Mater Sci Eng C 2011; 31 (08) 1632-1636
71 Jin HJ, Karageorgiou JPV, Kim UJ. , et al. Water-stable silk films with reduced β-sheet content. Adv Funct Mater 2005; 15 (08) 1241-1247
72 Lu Q, Hu X, Wang X. , et al. Water-insoluble silk films with silk I structure. Acta Biomater 2010; 6 (04) 1380-1387
73 Hofmann S, Foo CT, Rossetti F. , et al. Silk fibroin as an organic polymer for controlled drug delivery. J Control Release 2006; 111 (1–2): 219-227
74 Yu J, Zhang Y, Kahkoska AR, Gu Z. Bioresponsive transcutaneous patches. Curr Opin Biotechnol 2017; 48: 28-32
75 Chen G, Yu J, Gu Z. Glucose-responsive microneedle patches for diabetes treatment. J Diabetes Sci Technol 2019; 13 (01) 41-48
76 Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology 2011; 9: 55
77 Taghizadeh B, Taranejoo S, Monemian SA. , et al. Classification of stimuli-responsive polymers as anticancer drug delivery systems. Drug Deliv 2015; 22 (02) 145-155
78 Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013; 12 (11) 991-1003
79 Yu J, Zhang Y, Ye Y. , et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc Natl Acad Sci U S A 2015; 112 (27) 8260-8265
80 Zhang Y, Wang J, Yu J. , et al. Bioresponsive microneedles with a sheath structure for h2 o2 and ph cascade-triggered insulin delivery. Small 2018; 14 (14) e1704181
81 Romani N, Flacher V, Tripp CH, Sparber F, Ebner S, Stoitzner P. Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol 2012; 351: 113-138
82 Sparber F, Tripp CH, Hermann M, Romani N, Stoitzner P. Langerhans cells and dermal dendritic cells capture protein antigens in the skin: possible targets for vaccination through the skin. Immunobiology 2010; 215 (9–10): 770-779
83 Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol 2012; 351: 77-112
84 Segura E, Villadangos JA. Antigen presentation by dendritic cells in vivo. Curr Opin Immunol 2009; 21 (01) 105-110
85 Zaba LC, Krueger JG, Lowes MA. Resident and “inflammatory” dendritic cells in human skin. J Invest Dermatol 2009; 129 (02) 302-308
86 Quan FS, Kim YC, Compans RW, Prausnitz MR, Kang SM. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release 2010; 147 (03) 326-332
87 Song JM, Kim YC, , O E, Compans RW, Prausnitz MR, Kang SM. DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther 2012; 20 (07) 1472-1480
88 Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000; 6 (12) 1403-1406
89 Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002; 8 (04) 415-419
90 Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009; 27 (49) 6932-6938
91 Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4 (03) 211-222
92 Lin WH, Kouyos RD, Adams RJ, Grenfell BT, Griffin DE. Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci U S A 2012; 109 (37) 14989-14994
93 Simon ID, Publicover J, Rose JK. Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J Virol 2007; 81 (04) 2078-2082
94 Tam HH, Melo MB, Kang M. , et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc Natl Acad Sci U S A 2016; 113 (43) E6639-E6648
95 Zhao L, Seth A, Wibowo N. , et al. Nanoparticle vaccines. Vaccine 2014; 32 (03) 327-337
96 Demento SL, Cui W, Criscione JM. , et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 2012; 33 (19) 4957-4964
97 Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A 2012; 109 (04) 1080-1085
98 Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009; 21 (03) 346-351
99 Arya J, Prausnitz MR. Microneedle patches for vaccination in developing countries. J Control Release 2016; 240: 135-141
100 Wong KK, Li WA, Mooney DJ, Dranoff G. Advances in therapeutic cancer vaccines. Adv Immunol 2016; 130: 191-249
101 Tumeh PC, Harview CL, Yearley JH. , et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515 (7528): 568-571
102 Banchereau J, Palucka K. Immunotherapy: cancer vaccines on the move. Nat Rev Clin Oncol 2018; 15 (01) 9-10
103 Xia AL, Xu Y, Lu XJ. Cancer immunotherapy: challenges and clinical applications. J Med Genet 2019; 56 (01) 1-3
104 Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A 2014; 111 (34) 12288-12293
105 Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348 (6230): 56-61
106 Skyler JS. Diabetes mellitus: pathogenesis and treatment strategies. J Med Chem 2004; 47 (17) 4113-4117
107 Chen H, Zhu H, Zheng J. , et al. Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin. J Control Release 2009; 139 (01) 63-72
108 Wu Y, Gao Y, Qin G. , et al. Sustained release of insulin through skin by intradermal microdelivery system. Biomed Microdevices 2010; 12 (04) 665-671
109 Lee IC, Lin WM, Shu JC, Tsai SW, Chen CH, Tsai MT. Formulation of two-layer dissolving polymeric microneedle patches for insulin transdermal delivery in diabetic mice. J Biomed Mater Res A 2017; 105 (01) 84-93
110 Weinger K, Jacobson AM, Draelos MT, Finkelstein DM, Simonson DC. Blood glucose estimation and symptoms during hyperglycemia and hypoglycemia in patients with insulin-dependent diabetes mellitus. Am J Med 1995; 98 (01) 22-31
111 Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993; 91 (03) 819-828
112 Wilinska ME, Budiman ES, Taub MB. , et al. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Technol 2009; 3 (05) 1109-1120
113 Seong KY, Seo MS, Hwang DY. , et al. A self-adherent, bullet-shaped microneedle patch for controlled transdermal delivery of insulin. J Control Release 2017; 265: 48-56
114 Pettis RJ, Harvey AJ. Microneedle delivery: clinical studies and emerging medical applications. Ther Deliv 2012; 3 (03) 357-371
115 Bhatnagar S, Dave K, Venuganti VVK. Microneedles in the clinic. J Control Release 2017; 260: 164-182
116 Norman JJ, Brown MR, Raviele NA, Prausnitz MR, Felner EI. Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes. Pediatr Diabetes 2013; 14 (06) 459-465
117 Marshall S, Sahm LJ, Moore AC. Microneedle technology for immunisation: perception, acceptability and suitability for paediatric use. Vaccine 2016; 34 (06) 723-734
118 Nguyen TT, Park JH. Human studies with microneedles for evaluation of their efficacy and safety. Expert Opin Drug Deliv 2018; 15 (03) 235-245
119 Kochba E, Levin Y, Raz I, Cahn A. Improved insulin pharmacokinetics using a novel microneedle device for intradermal delivery in patients with type 2 diabetes. Diabetes Technol Ther 2016; 18 (09) 525-531
120 Gupta J, Felner EI, Prausnitz MR. Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. Diabetes Technol Ther 2009; 11 (06) 329-337
121 Hirobe S, Azukizawa H, Matsuo K. , et al. Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device. Pharm Res 2013; 30 (10) 2664-2674
122 Hirobe S, Azukizawa H, Hanafusa T. , et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials 2015; 57: 50-58